Fig. 2
From: Targeted inhibition of STAT/TET1 axis as a therapeutic strategy for acute myeloid leukemia
Therapeutic effects of NSC-311068 and NSC-370284 in AML in vivo. a NSC-311068 or NSC-370284 administration inhibits MLL-AF9-AML. The secondary BMT recipient mice were transplanted with leukemic BM blast cells collected from primary MLL-AF9 AML mice. Upon the onset of leukemia, the recipient mice were treated with DMSO (control; n = 5), 2.5 mg/kg NSC-311068 (n = 5) or NSC-370284 (n = 7), i.p., once per day, for 10 days. Kaplan–Meier curves are shown. The P values were determined by log-rank test. b Wright–Giemsa staining of mouse peripheral blood (PB) and BM, or hematoxylin and eosin (H&E) staining of mouse spleen and liver of the treated or control leukemic mice. c, d Tet1/2/3 gene expression levels (c), or Tet1 protein level (d), in BM blast cells of the treated or control leukemic mice. *P < 0.05, two-tailed t-test. Error bar indicates SD of triplicate experiments. e Effects of NSC-311068 and NSC-370284 on the AE9a-AML mouse model. The secondary BMT recipient mice were transplanted with leukemic BM blast cells collected from the primary AE9a-AML mice. Upon the onset of leukemia, the recipient mice were treated with DMSO (control; n = 5), 2.5 mg/kg NSC-311068 (n = 6) or NSC-370284 (n = 6), i.p., once per day, for 10 days. Kaplan–Meier curves are shown. The P values were determined by log-rank test
